Quantcast
Last updated on April 17, 2014 at 11:32 EDT

Latest Bare-metal stent Stories

2009-02-17 06:00:00

Company Also Names Richard Sahagian as Senior Scientist BURLINGTON, Mass., Feb. 17 /PRNewswire/ -- CorNova(R), Inc. today announced the expansion of its executive team with the appointment of Robert Gallahue as chief financial officer. The company also announced the addition of Richard Sahagian as senior scientist. (Logo: http://www.newscom.com/cgi-bin/prnh/20070206/CLTU213LOGO ) The appointments reflect the evolution of the company's endovascular product line, which includes the...

2009-02-03 07:32:00

PLATINUM clinical program to evaluate PROMUS(TM) Element(TM) Platinum Chromium Stent NATICK, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the beginning of patient enrollment in the PLATINUM clinical trial, which is designed to evaluate the Company's PROMUS(TM) Element(TM) Everolimus-Eluting Coronary Stent. The first U.S. patient was enrolled last week at the Medical Center of the Rockies in Loveland, Colorado by Thomas Downes, M.D. The...

2009-01-26 20:39:17

Coronary bypass surgery may carry less risk of serious complications if stents are coated with a drug that suppresses cell growth, U.S. researchers said. Researchers at the University of Texas Southwestern Medical Center in Dallas and colleagues said a multicenter trial compared two types of commonly used stents. Lead author Dr. Emmanouil Brilakis said stents are small mesh tubes that reinforce the walls of blocked blood vessels. In this study, stents were used to treat blockages in...

2009-01-22 10:13:04

Coronary bypass surgery may carry less risk of serious complications if stents coated with a drug that suppresses cell growth are used in the procedure rather than bare-metal stents, UT Southwestern Medical Center researchers and colleagues have found. The study, appearing online and in an upcoming issue of The Journal of the American College of Cardiology, is the first large, multicenter trial comparing two types of commonly used stents. Stents are small mesh tubes that reinforce the walls...

2009-01-12 14:37:00

Company In-licenses State-of-the-art CE-Marked Cobalt-Chromium Coronary Stent Forms Alliance to Jointly Develop Drug Eluting Balloon Products RALEIGH, N.C., Jan. 12 /PRNewswire/ -- Micell Technologies announced today that that the company entered into a strategic agreement with Maxcor Inc., the newly incorporated subsidiary of Opto Circuits (OCI) Ltd., by which Micell Technologies has obtained the rights to Maxcor's Genius MAGIC Cobalt Chromium Coronary Stent System for the purpose of...

2009-01-06 07:30:00

Acquisition demonstrates Company's commitment to innovation in drug-eluting stent technology NATICK, Mass., Jan. 6 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has acquired Labcoat Limited, a privately held, development-stage drug-eluting stent technology company located in Galway, Ireland. Terms of the acquisition were not disclosed. Labcoat has developed a novel technology for coating drug-eluting stents that uses precisely metered droplets...

2008-11-13 09:00:37

MOUNTAIN VIEW, Calif., Nov. 13 /PRNewswire/ -- Based on its recent analysis of the drug eluting stents (DES) market, Frost & Sullivan recognizes Boston Scientific with the 2008 North American Frost & Sullivan Market Leadership Award. This award highlights important milestones for Boston Scientific, including FDA approvals for the PROMUS(TM) Everolimus-Eluting Coronary Stent System, the TAXUS(R) Express2(TM) Atom(TM) Stent and the company's second-generation TAXUS(R) Liberte(R) Stent....

2008-10-15 12:00:33

NATICK, Mass. and WASHINGTON, Oct. 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced results from an analysis of the HORIZONS AMI trial. The HORIZONS AMI trial, sponsored by the Cardiovascular Research Foundation (CRF) with research grant support from Boston Scientific and The Medicines Company is designed to determine the safety and efficacy of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients...

2008-10-14 12:00:32

The latest update to an independently conducted pooled data analysis shows once again how the Endeavor drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT), is distinguished by persistently strong safety benefits for patients with coronary artery disease. Called ENDEAVOR-Safety, the analysis now includes more than 1,100 patients followed to four years. Compared to a bare-metal stent (n=596), the Endeavor DES (n=2,132) has been shown at four years to be associated with numerically...

2008-09-25 09:00:54

NATICK, Mass., Sept. 25 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Express2(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent System. The TAXUS Express Atom Stent is a highly deliverable drug-eluting stent (DES) specifically designed for treating small coronary vessels. It is the only DES approved by the FDA for use in vessels as small as 2.25 mm in diameter. No...